Foamix Pharmaceuticals Ltd. Deferred Tax Assets, in Process Research and Development
Foamix Pharmaceuticals Ltd. had Deferred Tax Assets, in Process Research and Development of $9.86 million as of 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2018-03-01
- 2017-12-31: Deferred Tax Assets, in Process Research and Development $9.86M.
- 2016-12-31: Deferred Tax Assets, in Process Research and Development $4.15M.
- 2015-12-31: Deferred Tax Assets, in Process Research and Development $1.77M.
- 2014-12-31: Deferred Tax Assets, in Process Research and Development $2.12M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2017-12-31 | $9.86M 10-K · filed 2018-03-01 |
| 2016-12-31 | $4.15M 10-K · filed 2018-03-01 |
| 2015-12-31 | $1.77M 20-F · filed 2017-02-21 |
| 2014-12-31 | $2.12M 20-F · filed 2016-03-02 |
| 2013-12-31 | $490.00K 20-F · filed 2015-03-17 |